Bank Julius Baer & Co. Ltd Zurich trimmed its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 18.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,232 shares of the biotechnology company’s stock after selling 11,028 shares during the period. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.18% of Arcturus Therapeutics worth $1,489,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also modified their holdings of the company. New York State Teachers Retirement System bought a new position in shares of Arcturus Therapeutics during the 3rd quarter valued at approximately $53,000. China Universal Asset Management Co. Ltd. increased its position in shares of Arcturus Therapeutics by 352.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,406 shares during the last quarter. Arizona State Retirement System bought a new position in shares of Arcturus Therapeutics during the 4th quarter valued at approximately $211,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Arcturus Therapeutics by 5.9% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,853 shares of the biotechnology company’s stock valued at $277,000 after purchasing an additional 606 shares during the last quarter. Finally, Stratos Wealth Partners LTD. bought a new position in shares of Arcturus Therapeutics during the 3rd quarter valued at approximately $301,000. 94.54% of the stock is owned by hedge funds and other institutional investors.
Arcturus Therapeutics Trading Up 1.5 %
Shares of ARCT stock opened at $26.55 on Friday. Arcturus Therapeutics Holdings Inc. has a twelve month low of $17.52 and a twelve month high of $43.81. The stock has a fifty day simple moving average of $33.73 and a two-hundred day simple moving average of $29.80.
Analysts Set New Price Targets
ARCT has been the topic of several analyst reports. Citigroup boosted their target price on Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, February 8th. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a research report on Friday, March 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $61.33.
View Our Latest Stock Analysis on ARCT
Insiders Place Their Bets
In other Arcturus Therapeutics news, COO Pad Chivukula sold 8,565 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $35.01, for a total value of $299,860.65. Following the completion of the sale, the chief operating officer now directly owns 490,883 shares in the company, valued at approximately $17,185,813.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 13.80% of the company’s stock.
Arcturus Therapeutics Profile
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Featured Articles
- Five stocks we like better than Arcturus Therapeutics
- 3 Fintech Stocks With Good 2021 Prospects
- MarketBeat Week in Review – 4/22 – 4/26
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Monster Growth Stocks to Buy Now
- How to Use Put Debit Spreads to Profit From Falling Stocks
Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report).
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.